Invivyd Appoints Michael Mina, M.D., Ph.D., As Chief Medical Officer To Advance Infectious Disease Prevention

Invivyd, Inc. announced today that Michael Mina, M.D., Ph.D., has been appointed as the company’s Chief Medical Officer. This appointment comes at a pivotal time for the company as it continues to develop solutions to protect against infectious diseases. 

Marc Elia, Chairman of Invivyd’s Board of Directors, said that Dr. Mina joins the company during a critical period in American healthcare and infectious disease prevention. “As we work to provide Americans with more options to protect themselves from viral threats such as COVID, Long COVID, RSV, and measles, Dr. Mina’s combination of medical training, epidemiology expertise, and deep knowledge of immunology, along with his proven ability to create practical solutions for complex problems, will help accelerate our efforts and support the expansion of our monoclonal antibody pipeline,” he said.

Dr. Mina expressed enthusiasm about joining Invivyd, stating that the company is at the forefront of advancing infectious disease prevention through monoclonal antibodies. He noted that he has had the opportunity to learn about the company’s technology platform and sees significant potential for medical impact. According to Dr. Mina, Invivyd is well-positioned to improve both the treatment and prevention of critical viral diseases that require better options.

Dr. Mina has a distinguished career in medicine and public health. He previously served as an assistant professor at the Harvard T.H. Chan School of Public Health, Harvard Medical School, and Brigham and Women’s Hospital. He has also held leadership roles as chief science or chief medical officer at several diagnostics and digital health companies. 

He rose to prominence during the COVID-19 pandemic by advising U.S. and international governments on testing strategies and advocating for a public health approach focused on identifying contagious individuals to reduce transmission and support society’s reopening. He also helped lead the U.S. Home Test-to-Treat Program, which improved access to treatments for underserved populations for both influenza and COVID-19.

Earlier in his career, Dr. Mina made important contributions to the study of measles, including the discovery of “immune amnesia,” a condition in which measles infection erases previous immune memory. His research has also focused on how the body responds to influenza and other vaccines, particularly in children and during pregnancy, with attention to the transfer of antibodies to newborns. 

He has led large population studies examining the human antibody response to hundreds of pathogens and autoimmune diseases, providing valuable insight into how immune systems develop, stabilize, and change over a lifetime. Dr. Mina’s extensive experience in public health strategy, viral immunology, and communication of complex scientific concepts positions him to help Invivyd advance its mission in passive antibody prophylaxis and the treatment of multiple infectious diseases.